News

In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...

West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.

MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.

MMSI vs. WST: Which Stock Is the Better Value Option?

SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.

DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.

SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

AVTR's shares jump nearly 7% as NuSil expands its HIV prevention partnership for a three-month dapivirine vaginal ring.

Over the past six months, West Pharmaceutical Services has been a great trade, beating the S&P 500 by 21.8%. Its stock price has climbed to $353.68, representing a healthy 30.1% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect.

GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.

Butterfly Network's partner Aleph Neuro showcases non-invasive 3D brain imaging, highlighting the reach of its Ultrasound-on-Chip platform.

In recent days, West Pharmaceutical Services reported revenue growth of 21%, reflecting increasing demand for its advanced drug containment and delivery solutions across healthcare markets. Analysts responded with a broadly positive outlook, highlighting how the company’s proprietary and contract-manufactured products may reinforce its role in supporting complex injectable therapies. Next, we’ll explore how this revenue surge and upbeat analyst sentiment might influence West Pharmaceutical...

GE HealthCare's Allia upgrade pathways let providers modernize legacy imaging systems with AI-enabled workflows while reducing construction and disruption.

West Pharmaceutical Services recently reported strong first-quarter 2026 results, highlighting robust growth in biologics-related high-value components and self-injection delivery devices, and raised its full-year 2026 revenue and adjusted EPS guidance. The company emphasized its role as a critical part of injectable-drug infrastructure rather than a conventional packaging supplier, underlining how its specialized high-value products support complex biologic therapies. Next, we’ll examine...

West Pharmaceutical continues to outpace broader market gains on strong earnings momentum and supportive analyst sentiment.

OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.

SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.

The updated analyst narrative for West Pharmaceutical Services now reflects a fair value estimate of US$352.36 per share, up from US$349.85. This refinement sits alongside fresh company guidance for Q2 2026 net sales, a recent buyback of 1,222,019 shares for US$297.65 million, and an announced leadership transition planned for the second half of 2026. Read on to see how these moving parts fit together and how you can keep track of the evolving story. Wall Street's queuing for one rocket...

Cooper Companies beats Q2 EPS and sales estimates as CooperVision and CooperSurgical hit record revenues, even with a GAAP loss from recall litigation.

Veeva Systems beats Q1 earnings and revenue estimates, raises fiscal 2027 guidance, and expands AI offerings as adoption of its software platforms expands.